Role of chemotherapy in the management of soft tissue sarcomas

Krikelis, Dimitrios; Judson, Ian

doi:10.1586/era.09.176

Cited by 67 publications

(47 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…78,79 The failure of these systemic treatments has been attributed to the resistance of presumably quiescent mesenchymal cancer stem cells to standard chemotherapeutic agents. [80][81][82] To study these tumors in-vivo, Zhang et al established a cell line of fibrosarcoma derived from transformed murine mesenchymal stem cells. 83 These cells stained positively for the vimentin, S-100, and a-SMA, consistent with a mesenchymal origin.…”

Section: Sarcomamentioning

confidence: 99%

LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential

Zhang

et al. 2015

Cancer Biology & Therapy

103

View full text Add to dashboard Cite

Section: Sarcomamentioning

confidence: 99%

LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential

Zhang

et al. 2015

Cancer Biology & Therapy

103

View full text Add to dashboard Cite

“…There is increasing specialisation of chemotherapy according to histological subtype, such as the use of taxanes for angiosarcoma, gemcitabine and docetaxel for leiomyosarcoma, and trabectedin for leiomyosarcoma and myxoid/round cell liposarcoma. 32 …”

Section: Chemotherapymentioning

confidence: 99%

Retroperitoneal tumours: review of management

Strauß

Hayes

Thomas

2011

annals

138

View full text Add to dashboard Cite

The retroperitoneum can host a wide spectrum of pathologies, including a variety of rare benign tumours and malignant neoplasms that can be either primary or metastatic lesions. Malignant tumours of the retroperitoneum occur four times more frequently than benign lesions.1 Sarcomas comprise a third of retroperitoneal tumours. Soft tissue sarcomas are rare tumours, with retroperitoneal sarcomas expected to compose approximately 15% of the 2,000 cases of soft tissue sarcomas anticipated in England and Wales each year.2 In the UK there are estimated to be between 250 and 300 new diagnoses of retroperitoneal sarcoma (RPS) each year. The retroperitoneum represents the second most common site of origin of malignant mesenchymal tumours after the lower extremities.3 Retroperitoneal tumours present several therapeutic challenges because of their relative late presentation and anatomical location (Fig 1). 4 This review highlights the presentation, evaluation and initial management of patients presenting with retroperitoneal tumours and the surgical management of RPS.A comprehensive literature search was conducted using PubMed. Relevant international articles published in the last ten years were assessed. The keywords for search purposes included: retroperitoneum, benign, sarcoma, neoplasm, diagnosis and surgery, radiotherapy, chemotherapy. The search was limited to articles published in English. All articles were read in full by the authors and selected for inclusion based on relevance to this article. BackgroundThe retroperitoneum represents a complex potential space with multiple vital structures bounded anteriorly by the peritoneum, ipsilateral colon and mesocolon, pancreas, liver or stomach. The posterior margins are by large composed of the psoas, quadratus lumborum, transverse abdominal and iliacus muscles but, depending on the tumour location and size, may be formed by the diaphragm, ipsilateral kidney, ureter and gonadal vessels. Similarly, the medial boundaries may include the spine, paraspinous muscles, the inferior vena cava (for right-sided tumours) and the aorta (for leftsided tumours). The lateral margin is formed by the lateral abdominal musculature and, depending on tumour location, may include the kidney and colon. Superiorly, retroperitoneal tumours may be in contact with the diaphragm, the right lobe The retroperitoneum can host a wide spectrum of pathologies, including a variety of rare benign tumours and malignant neoplasms that can be either primary or metastatic lesions. Retroperitoneal tumours can cause a diagnostic dilemma and present several therapeutic challenges because of their rarity, relative late presentation and anatomical location, often in close relationship with several vital structures in the retroperitoneal space. maTERiaLS and mEThodS a comprehensive literature search was conducted using Pubmed. Relevant international articles published in the last ten years were assessed. The keywords for search purposes included: retroperitoneum, benign, sarcoma, neoplasm, diagnosis and surgery, ra...

show abstract

“…Recently, trabectedin, a natural marine derived product, has emerged as an active agent, particularly in some subtypes such as myxoid/ round cell liposarcoma, refractory to anthracyclines and ifosfamide [3,4]. In addition other histological subtypes could be offered other systemic therapy regimens, such as gemcitabine and docetaxel in leiomyosarcoma and pegylated liposomal doxorubicin in angiosarcoma [2,5].…”

Section: Purposementioning

confidence: 99%